Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial

Original research

par

McAnulty, Christina et al

Date de publication

2022

Géographie

Canada

Langue de la ressource

English

Texte disponible en version intégrale

Oui

Open Access / OK to Reproduce

Oui

Évalué par des pairs

Yes

L’objectif

We compared the effectiveness of BUP/NX flexible model of care relative to methadone for craving reduction in individuals with prescription-type opioid use disorder (POUD).

Constatations/points à retenir

Compared to the standard methadone model of care, flexible take-home dosing of BUP/NX was associated with lower craving in individuals with POUD.

La conception ou méthodologie de recherche

Data from a multicentric, pragmatic, 24-week open-label randomized controlled trial (n=272)

doi.org

Mots clés

Substitution/OAT

Carries/take-home doses